SG11201809993VA - Oncolytic viruses comprising esrage and methods of treating cancer - Google Patents

Oncolytic viruses comprising esrage and methods of treating cancer

Info

Publication number
SG11201809993VA
SG11201809993VA SG11201809993VA SG11201809993VA SG11201809993VA SG 11201809993V A SG11201809993V A SG 11201809993VA SG 11201809993V A SG11201809993V A SG 11201809993VA SG 11201809993V A SG11201809993V A SG 11201809993VA SG 11201809993V A SG11201809993V A SG 11201809993VA
Authority
SG
Singapore
Prior art keywords
international
esrage
methods
pct
oncolytic viruses
Prior art date
Application number
SG11201809993VA
Inventor
Balveen Kaur
Ji Young Yoo
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of SG11201809993VA publication Critical patent/SG11201809993VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit Ill Hot 0 Oil m° mi minim° oimIE (10) International Publication Number WO 2017/197207 Al (51) International Patent Classification: A61K 48/00 (2006.01) C12Q 1/70 (2006.01) C12Q 1/68 (2006.01) (21) International Application Number: PCT/US2017/032300 (22) International Filing Date: 11 May 2017 (11.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/334,589 11 May 2016 (11.05.2016) US (71) Applicant: OHIO STATE INNOVATION FOUN- DATION [US/US]; 1524 North High Street, Columbus, Ohio 43201 (US). (72) Inventors: KAUR, Balveen; MSE.R129, 6431 Fannin St , Houston, Texas 77030 (US). YOO, Ji Young; MSE.R129, 6431 Fannin St , Houston, Texas 77030 (US). (74) Agent: LANIER, J. Gibson et al.; Meunier Carlin & Cuff- man LLC, 999 Peachtree St. NE, Suite 1300, Atlanta, Geor- gia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: ONCOLYTIC VIRUSES COMPRISING ESRAGE AND METHODS OF TREATING CANCER FIG. 2A. 0.3 c , 0.2- 0 0.1- © N 0.0 N control +antil-IMGB1 +esRAGE LN229 LN229+OV **** C (57) : Disclosed are novel modified or engineered oncolytic viruses comprising an esRAGE gene and methods for using said oncolytic virus for the treatment of a cancer.
SG11201809993VA 2016-05-11 2017-05-11 Oncolytic viruses comprising esrage and methods of treating cancer SG11201809993VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662334589P 2016-05-11 2016-05-11
PCT/US2017/032300 WO2017197207A1 (en) 2016-05-11 2017-05-11 Oncolytic viruses comprising esrage and methods of treating cancer

Publications (1)

Publication Number Publication Date
SG11201809993VA true SG11201809993VA (en) 2018-12-28

Family

ID=60266890

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809993VA SG11201809993VA (en) 2016-05-11 2017-05-11 Oncolytic viruses comprising esrage and methods of treating cancer

Country Status (10)

Country Link
US (1) US20190202886A1 (en)
EP (1) EP3454911A4 (en)
JP (1) JP2019518735A (en)
KR (1) KR20190003992A (en)
CN (1) CN109328075A (en)
AU (1) AU2017263543A1 (en)
BR (1) BR112018073238A2 (en)
CA (1) CA3023972A1 (en)
SG (1) SG11201809993VA (en)
WO (1) WO2017197207A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3638304A4 (en) * 2017-06-12 2021-02-24 Washington University Zika virus strains for treatment of glioblastoma
CN107955840A (en) * 2017-12-13 2018-04-24 华南农业大学 For detecting double PCR primer, detection method and the kit of swine foot-and-mouth disease virus and Sai Neijia paddy virus
KR20200139738A (en) * 2018-04-02 2020-12-14 듀크 유니버시티 Neoadjuvant cancer treatment
RU2692628C1 (en) * 2018-07-04 2019-06-25 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) RECOMBINANT VARIOLOVACCINE VIRUS STRAIN VV-NS1-dGF PRODUCING NS1 PARVOVIRUS H-1 PROTEIN AND HAVING ONCOLYTIC ACTIVITY ON HUMAN GLIOBLASTOMA
CN109022616B (en) * 2018-07-25 2021-11-12 广州烨善生物科技有限公司 Probe for detecting oncolytic virus and application thereof
CN109234464A (en) * 2018-11-23 2019-01-18 山东新希望六和集团有限公司 For detecting primer and probe, the PCR kit for fluorescence quantitative and methods and applications of Seneca Valley virus
WO2020143221A1 (en) * 2019-01-07 2020-07-16 四川安可康生物医药有限公司 Immune-oncolytic virus combination drug for enhancing systemic immune response and application thereof
US20200215133A1 (en) * 2019-01-07 2020-07-09 Sichuan Oncocare Biopharmaceutical, Inc. Combination of immuno-oncolytic virus drugs for enhancing systemic immune response and application thereof
CN113874032A (en) * 2019-05-15 2021-12-31 科达金尼克斯有限公司 Attenuated yellow fever virus and use thereof for cancer therapy
CN113717953A (en) * 2021-08-05 2021-11-30 北京舜雷科技有限公司 Application of attenuated flavivirus in oncolytic
CN113908256B (en) * 2021-11-26 2023-05-26 中国农业科学院兰州兽医研究所 Application of LANCL1 protein in preparing antiviral drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3837494B2 (en) * 2001-03-19 2006-10-25 国立大学法人金沢大学 Soluble RAGE protein
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
CA2577692C (en) * 2004-08-20 2014-05-06 Viralytics Limited Methods and compositions for treatment of hematologic cancers
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
WO2009135614A2 (en) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Use of a virus regimen for the treatment of diseases
JP2010233542A (en) * 2009-03-31 2010-10-21 Kanazawa Univ Primer set and probe capable of distinguishing and amplifying two kinds of splicing variants of rage gene
JP6415977B2 (en) * 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ Cloned strain of attenuated vaccinia virus and method of using the same
EP2922564B1 (en) * 2012-11-21 2018-07-04 Duke University Oncolytic poliovirus for human tumors

Also Published As

Publication number Publication date
WO2017197207A1 (en) 2017-11-16
US20190202886A1 (en) 2019-07-04
EP3454911A1 (en) 2019-03-20
CA3023972A1 (en) 2017-11-16
JP2019518735A (en) 2019-07-04
BR112018073238A2 (en) 2019-02-19
KR20190003992A (en) 2019-01-10
EP3454911A4 (en) 2019-11-13
AU2017263543A1 (en) 2018-12-13
CN109328075A (en) 2019-02-12

Similar Documents

Publication Publication Date Title
SG11201809993VA (en) Oncolytic viruses comprising esrage and methods of treating cancer
SG11201900815UA (en) Expression of pten-long with ocolytic viruses
SG11201804528YA (en) Multi-passenger ride vehicle
SG11201804696RA (en) Techniques for metadata processing
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201810210UA (en) Engineered botulinum neurotoxins
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201909949XA (en) Targeted immunotolerance
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201811432WA (en) Rna for cancer therapy
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201805577XA (en) Techniques for manipulation of two-qubit quantum states and related systems and methods
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201811034PA (en) Air treatment systems and methods
SG11201808422QA (en) Gene therapy for treating hemophilia a
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer